Samsung BioLogics Plans $2.7 Billion IPO in South Korea

On Thursday of this week, Samsung BioLogics is expected to file for an IPO on South Korea's main board that will raise between $1.8 and $2.7 billion, valuing the company at $9 billion. Samsung BioLogics, the biopharma subsidiary of electronics conglomerate Samsung, aims to become the world's largest biologic drug CMO. It is also developing its own biosimilar drugs. According to IMS, the global market for biologic drugs will be over $390 billion by 2020 -- representing nearly one out of every three dollars spent for drugs -- which explains why so many pharmas are investing in biologic/biosimilar infrastructure. More details.... Share this with colleagues: // //